{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:48:56Z","timestamp":1787759336512,"version":"build-2784847793"},"reference-count":30,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Cubist Pharmaceuticals"}],"content-domain":{"domain":["clinicalkey.jp","ijaaonline.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.ijantimicag.2015.07.004","type":"journal-article","created":{"date-parts":[[2015,8,10]],"date-time":"2015-08-10T12:15:25Z","timestamp":1439208925000},"page":"502-510","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["In vitro activity of ceftolozane\/tazobactam against clinical isolates of Pseudomonas aeruginosa and Enterobacteriaceae recovered in Spanish medical centres: Results of the CENIT study"],"prefix":"10.1016","volume":"46","author":[{"given":"Marta","family":"Tato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Garc\u00eda-Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Moreno","family":"Bofarull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Cant\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2015.07.004_bib0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/668770","article-title":"Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009\u20132010","volume":"34","author":"Sievert","year":"2013","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.ijantimicag.2015.07.004_bib0160","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1749-7922-7-15","article-title":"Complicated intra-abdominal infections in Europe: preliminary data from the first three months of the CIAO Study","volume":"7","author":"Sartelli","year":"2012","journal-title":"World J Emerg Surg"},{"key":"10.1016\/j.ijantimicag.2015.07.004_bib0165","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.ijantimicag.2014.01.007","article-title":"Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: results from the SENTRY Antimicrobial Surveillance Program, 2009\u20132012","volume":"43","author":"Sader","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2015.07.004_bib0170","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1093\/jac\/dkr231","article-title":"Changing epidemiology of central venous catheter-related bloodstream infections: increasing prevalence of Gram-negative pathogens","volume":"66","author":"Marcos","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2015.07.004_bib0175","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1056\/NEJMra0904124","article-title":"Hospital-acquired infections due to Gram-negative bacteria","volume":"362","author":"Peleg","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2015.07.004_bib0180","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s15010-011-0124-6","article-title":"Impact of inappropriate empiric antimicrobial therapy on outcome in Pseudomonas aeruginosa bacteraemia: a stratified analysis according to sites of infection","volume":"39","author":"Joo","year":"2011","journal-title":"Infection"},{"key":"10.1016\/j.ijantimicag.2015.07.004_bib0185","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1471-2334-12-56","article-title":"An institutional perspective on the impact of recent antibiotic exposure on length of stay and hospital costs for patients with Gram-negative sepsis","volume":"12","author":"Micek","year":"2012","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijantimicag.2015.07.004_bib0190","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1128\/AAC.01041-09","article-title":"Attributable hospital cost and length of stay associated with health care-associated infections caused by antibiotic-resistant Gram-negative bacteria","volume":"54","author":"Mauldin","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.07.004_bib0195","series-title":"24th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)","article-title":"Efficacy and safety of ceftolozane\/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTI) including pyelonephritis in hospitalized adults: results from the phase 3 ASPECT-cUTI trial","author":"Wagenlehner","year":"2014"},{"key":"10.1016\/j.ijantimicag.2015.07.004_bib0200","series-title":"24th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)","article-title":"Efficacy and safety of ceftolozane\/tazobactam versus meropenem in the treatment of complicated intra-abdominal infections (cIAI) in hospitalized adults: results from the phase 3 ASPECT-cIAI trial","author":"Eckmann","year":"2014"},{"key":"10.1016\/j.ijantimicag.2015.07.004_bib0205","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40265-013-0168-2","article-title":"Ceftolozane\/tazobactam: a novel cephalosporin\/\u03b2-lactamase inhibitor combination with activity against multidrug-resistant Gram-negative bacilli","volume":"74","author":"Zhanel","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2015.07.004_bib0210","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1128\/AAC.01737-10","article-title":"Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes","volume":"55","author":"Sader","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.07.004_bib0215","doi-asserted-by":"crossref","first-page":"6305","DOI":"10.1128\/AAC.01802-13","article-title":"Antimicrobial activity of ceftolozane\u2013tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. hospitals (2011\u20132012)","volume":"57","author":"Farrell","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.07.004_bib0220","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.diagmicrobio.2011.02.004","article-title":"In vitro activity of CXA-101 plus tazobactam (CXA-201) against CTX-M-14- and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae","volume":"70","author":"Titelman","year":"2011","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2015.07.004_bib0225","unstructured":"European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe. Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net) 2012. ECDC. http:\/\/ecdc.europa.eu\/en\/publications\/Publications\/antimicrobial-resistance-surveillance-europe-2012.pdf [accessed 28.07.15]."},{"key":"10.1016\/j.ijantimicag.2015.07.004_bib0230","unstructured":"International Organization for Standardization. ISO 20776-1:2006. Clinical laboratory testing and in vitro diagnostic test systems\u2014Susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices\u2014Part 1: Reference method for testing the in vitro activity of antimicrobial agents against rapidly growing aerobic bacteria involved in infectious diseases. http:\/\/www.iso.org\/iso\/catalogue_detail.htm?csnumber=41630 [accessed 23.12.14]."},{"key":"10.1016\/j.ijantimicag.2015.07.004_bib0235","series-title":"Breakpoint tables for interpretation of MICs and zone diameters. Version 4.0, 2014","author":"European Committee on Antimicrobial Susceptibility Testing","year":"2014"},{"key":"10.1016\/j.ijantimicag.2015.07.004_bib0240","series-title":"Performance standards for antimicrobial susceptibility testing; twenty-third informational supplement. Document M100-S23","author":"Clinical and Laboratory Standards Institute","year":"2013"},{"key":"10.1016\/j.ijantimicag.2015.07.004_bib0245","series-title":"Cubist Pharmaceuticals Prescribing information for ZERBAXA\u2122","year":"2015"},{"key":"10.1016\/j.ijantimicag.2015.07.004_bib0250","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard\u2014ninth edition. Document M07-A9","author":"Clinical and Laboratory Standards Institute","year":"2012"},{"key":"10.1016\/j.ijantimicag.2015.07.004_bib0255","series-title":"EUCAST guidelines for detection of resistance mechanisms and specific resistances of clinical and\/or epidemiological importance. Version 1.0, December 2013","author":"European Committee on Antimicrobial Susceptibility Testing","year":"2013"},{"key":"10.1016\/j.ijantimicag.2015.07.004_bib0260","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1093\/clinids\/10.4.867","article-title":"Extended broad-spectrum \u03b2-lactamases conferring transferable resistance to newer \u03b2-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns","volume":"10","author":"Jarlier","year":"1988","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.ijantimicag.2015.07.004_bib0265","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.3201\/eid1809.120355","article-title":"Rapid detection of carbapenemase-producing Enterobacteriaceae","volume":"18","author":"Nordmann","year":"2012","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.ijantimicag.2015.07.004_bib0270","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/1469-0691.12322","article-title":"A disc diffusion assay for detection of class A, B and OXA-48 carbapenemases in Enterobacteriaceae using phenyl boronic acid, dipicolinic acid and temocillin","volume":"20","author":"van Dijk","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2015.07.004_bib0275","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1128\/CMR.8.4.557","article-title":"\u03b2-Lactamases in laboratory and clinical resistance","volume":"8","author":"Livermore","year":"1995","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2015.07.004_bib0280","doi-asserted-by":"crossref","first-page":"546","DOI":"10.3201\/eid1104.040699","article-title":"Antimicrobial-resistant invasive Escherichia coli","volume":"11","author":"Oteo","year":"2005","journal-title":"Spain. Emerg Infect Dis"},{"key":"10.1016\/j.ijantimicag.2015.07.004_bib0285","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.3201\/eid1411.070467","article-title":"Antimicrobial drug use and resistance in Europe","volume":"14","author":"van de Sande-Bruinsma","year":"2008","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.ijantimicag.2015.07.004_bib0290","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1093\/jac\/dkq248","article-title":"Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus \u03b2-lactamase-producing Enterobacteriaceae","volume":"65","author":"Livermore","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2015.07.004_bib0295","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1128\/AAC.00860-06","article-title":"In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa","volume":"51","author":"Takeda","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2015.07.004_bib0300","doi-asserted-by":"crossref","first-page":"5707","DOI":"10.1128\/AAC.01404-13","article-title":"In vitro activity of ceftolozane\u2013tazobactam against Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals in the CANWARD study, 2007 to 2012","volume":"57","author":"Walkty","year":"2013","journal-title":"Antimicrob Agents Chemother"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857915002721?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857915002721?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T02:22:34Z","timestamp":1567045354000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857915002721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S0924857915002721"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2015.07.004","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro activity of ceftolozane\/tazobactam against clinical isolates of Pseudomonas aeruginosa and Enterobacteriaceae recovered in Spanish medical centres: Results of the CENIT study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2015.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}